|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 1. Baseline and Operative Characteristics of the Patients.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic n(%)** | **Repair**  | **Replacement** | **P value** |
| **Male sex** |  |  |  |
| **Age** |  |  |  |
| **White race** |  |  |  |
| **Hispanic ethnic group** |  |  |  |
| **Medical and surgical history** |  |  |  |
| **Diabetes** |  |  |  |
| **Renal insufficiency** |  |  |  |
| **Previous CABG** |  |  |  |
| **Previous PCI** |  |  |  |
| **Heart failure** |  |  |  |
| **Myocardial infarction** |  |  |  |
| **Atrial fibrillation** |  |  |  |
| **Implantable cardioverter–defibrillator** |  |  |  |
| **Stroke** |  |  |  |
| **Left ventricular ejection fraction** |  |  |  |
| **Effective regurgitant orifice area (cm2)** |  |  |  |
| **CCS angina scale Grade III or IV** |  |  |  |
| **No angina** |  |  |  |
| **NYHA class III or IV** |  |  |  |
| **Minnesota Living with Heart Failure score** |  |  |  |
| **Concomitant CABG** |  |  |  |
| **STS Score**  |  |  |  |
| **COPD** |  |  |  |

**Table 2. Clinical End Points, Serious Adverse Events, and Hospitalizations at 30 Days and 1 Year.**

|  |  |  |
| --- | --- | --- |
| **Clinical End point** | **30 days** | **1 year** |
| **Repair** | **Replacement** | **P** | **Repair** | **Replacement** | **p** |
| **Death** |  |  |  |  |  |  |
| **Stroke** |  |  |  |  |  |  |
| **Worsening in NYHA class of ⩾1** |  |  |  |  |  |  |
| **Rehospitalization for heart failure** |  |  |  |  |  |  |
| **Mitral-valve reoperation** |  |  |  |  |  |  |
| **Composite major adverse event** |  |  |  |  |  |  |
| **Serious adverse event** |  |  |  |  |  |  |
| **Heart failure** |  |  |  |  |  |  |
| **Stroke** |  |  |  |  |  |  |
| **Other neurologic dysfunction** |  |  |  |  |  |  |
| **Myocardial infarction** |  |  |  |  |  |  |
| **Renal failure** |  |  |  |  |  |  |
| **Bleeding** |  |  |  |  |  |  |
| **Arrhythmia** |  |  |  |  |  |  |
|  **Supraventricular** |  |  |  |  |  |  |
|  **Ventricular** |  |  |  |  |  |  |
| **Localized infection** |  |  |  |  |  |  |
| **Sepsis** |  |  |  |  |  |  |
| **Respiratory failure** |  |  |  |  |  |  |
| **Any rehospitalization** |  |  |  |  |  |  |
| **Cardiac Readmission** |  |  |  |  |  |  |
|  |  |  |  |  |  |  |

 |